Probiotics for Cardiometabolic Health

The gut-cardiovascular axis describes the relationship between gut microbiome composition and cardiovascular health markers, particularly lipid metabolism, maintaining cholesterol regulation in a healthy range, and supporting healthy inflammatory signaling pathways that influence heart health. Research demonstrates that gut bacteria can influence several molecules linked to lipid metabolism, including bile acids, short-chain fatty acids (SCFAs), and other metabolites that affect how cholesterol is processed and transported in the body.

This axis is the scientific foundation that makes a probiotic ingredient relevant to a heart health or cholesterol wellness formulation. Rather than acting on cholesterol directly, precision probiotic strains can target the specific gut microbiome processes that influence and help support healthy lipid metabolism, enabling a mechanism-driven positioning strategy grounded in the gut-liver connection.

The gut microbiome influences lipid metabolism through three primary interconnected mechanisms: bile salt hydrolase (BSH) enzyme activity, short-chain fatty acid (SCFA) production, and gut-liver axis signaling — each representing a distinct pathway through which specific probiotic strains can support healthy lipid profiles.

Lactiplantibacillus plantarum KABP® 011, KABP® 012, and KABP® 013 are among the most clinically substantiated probiotic strains available for cardiometabolic health applications, combining strain-specific mechanistic evidence with a robust human clinical research base.

These three strains form the basis of KABP® Metaguard, a triple-strain formulation derived from healthy human gut microflora and specifically developed to support and help maintain healthy total cholesterol, LDL, HDL, and triglyceride levels already in the normal range in healthy individuals. KABP® Metaguard is supported by seven clinical studies and has won the NutraIngredients Award in both 2018 and 2025.

The published research base includes randomized clinical trials evaluating the cholesterol-related outcomes of this specific L. plantarum strain combination, providing the kind of indication-matched, strain-level evidence that brands need to substantiate cardiometabolic claims compliantly and credibly.

Supporting already healthy cholesterol levels is a structure/function claim applicable to healthy individuals whose cholesterol is already within a normal range, describing a product’s role in maintaining that balance through gut microbiome modulation. Treating high cholesterol is a disease claim, applicable only to pharmaceutical interventions regulated by the FDA, and is not an appropriate positioning for dietary supplement probiotic products regardless of the underlying evidence.

KABP® Metaguard is specifically developed and clinically studied within the “supporting already healthy cholesterol” framework, with indications written to reflect support for levels already in the normal range in healthy individuals.

The primary clinical biomarkers used to evaluate probiotic efficacy in cardiometabolic applications are the standard lipid panel markers: total cholesterol, LDL cholesterol (low-density lipoprotein), HDL cholesterol (high-density lipoprotein), and triglycerides. These four markers collectively represent the most widely recognized and commercially relevant measures of lipid health, and they are the specific outcomes supported by KABP® Metaguard across its clinical evidence base.

Beyond the core lipid panel, secondary biomarkers increasingly used in cardiometabolic probiotic research include inflammatory markers such as high-sensitivity C-reactive protein (hs-CRP), TNF-α, and IL-6, which reflect the inflammatory component of cardiovascular risk. Some studies also evaluate bile acid profiles and SCFA concentrations as mechanistic indicators of how a probiotic strain is interacting with the gut-liver axis.